secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093294
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160
---------------------------------------------------------------------

- Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.
- Cash, equivalents, securities $267.1M at June 30, 2024; expected to fund operations into H1 2027.
- IND accepted by FDA for VAV1-directed MGD MRT-6160; Phase 1 SAD/MAD to start summer with data expected Q1 2025.
- MRT-2359 Phase 1/2 dose escalation ongoing at 0.75 mg 21/7 schedule; RP2D determination and updated results expected H2 2024.
- Achieved first research milestones and payments from Roche collaboration; $100M public offering completed in May.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/0000950170-24-093294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/glue-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer